Agenda-setting intelligence, analysis and advice for the global fashion community.
Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs to have its price slashed in bargaining with the US government, a company executive said.
Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice. Or get in touch at support@businessoffashion.com if you experience difficulties.




